8 companies

Showing 1–8 of 8 companies

Egetis Therapeutics AB

Specialty pharmaceutical company developing and commercialising treatments for rare diseases, led by Emcitate (tiratricol) for MCT8 deficiency.

1 open job

Orchard Therapeutics

Orchard Therapeutics develops ex vivo autologous HSC gene therapies for rare genetic diseases; its Libmeldy is the first FDA-approved therapy for metachromatic leukodystrophy.

1 open job

Tangram Therapeutics

Tangram Therapeutics is a biotechnology company using AI and RNAi to develop genetic medicines.

1 open job

ATB Therapeutics

Belgian biopharmaceutical company developing bifunctional antibody (atbody) therapeutics for cancer and autoimmune disease via its atbiofarm single-step manufacturing platform.

Monte Rosa Therapeutics

Monte Rosa Therapeutics develops clinical-stage molecular glue degrader medicines using an AI-guided discovery engine targeting undruggable proteins.

1 open job

Nucleome Therapeutics

Nucleome Therapeutics is an Oxford-based biotech company using 3D genome sequencing and machine learning to decode the dark genome and develop precision medicines for immune-mediated inflammatory diseases.

Relation Therapeutics

Relation Therapeutics is a London-based TechBio firm using active-graph machine learning, single-cell multi-omics and clinical data to discover medicines, starting with bone diseases such as osteoporosis.

1 open job

MeiraGTx

MeiraGTx is a clinical-stage genetic medicine company developing therapies for diseases using viral vectors and a riboswitch gene regulation platform.

8 companies

Egetis Therapeutics AB

Orchard Therapeutics

Tangram Therapeutics

ATB Therapeutics

Monte Rosa Therapeutics

Nucleome Therapeutics

Relation Therapeutics

MeiraGTx

Browse by market